Recent Publications

Recent Representation Publications (out of > 350 total)

 

Peer reviewed articles

 

Ghiassi-Nejad Z, Hernandez-Gea V, Woodrell C, Lang UE, Dumic K, Kwong A, Friedman SL. Reduced hepatic stellate cell expression of Kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury. Hepatology. 57(2):786-96, 2013. PMID:22961688

 

Lang UE, Kocabayoglu P, Cheng GZ, Ghiassi-Nejad Z, Muñoz U, Vetter D, Eckstein DA, Hannivoort RA, Walsh MJ, Friedman SL. GSK3β phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21. Oncogene, 2(38):4557-64, 2013.

 

Hong F, Chou HI, Fiel MI, Friedman SL. Antifibrotic activity of sorafenib in experimental hepatic fibrosis – refinement of inhibitory targets, dosing and window of efficacy in vivo. Digestive Diseases and Sciences, 58(1):257-64 , 2013.

 

Hernández-Gea V, Hilscher M, Rozenfeld R, Lim MP , Nieto N, Werner S, Devi LA and Friedman SL. Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy.   Journal of Hepatology, 59(1):98-104, 2013.

 

Saiman Y, Jiao J, Fiel MI, Friedman SL, Aloman C, Bansal MB. Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury. Hepatol Res. 45(7):794-803, 2015.

 

King LY, Canasto-Chibuque C, Johnson K, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan PS, Sun X, Villanueva A, Sangiovanni A, Nair V, Mahajan M, Kobayashi M, Kumada H, Iavarone M, Colombo M, Fiel MI, Friedman SL, Llovet JM, Chung RT, Hoshida Y. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut, 64:1296-1302, 2015.

Kocabayoglu P, Lade A, Dragomir A-C, Lee YA, Sun X, Fiel MI, Thung S, Aloman C, Soriano P, Hoshida Y, Friedman SL. β-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis. Journal of Hepatology, 63(1):141-7, 2015.

Hasegawa D, Calvo V, Avivar-Valderas A, Lade A., Chou H, Lee, Y.A, Farias E, Aguirre-Ghiso JA, Friedman SL. Epithelial Xbp1 is required for cellular proliferation and differentiation during mammary gland development. Molecular and Cellular Biology, 35:1543-1556, 2015.

 

Zhang DY, Goossens N, Guo J, Tsai M-C, Chou HI, Altunkaynak C, Sangiovanni A, Ivarone M, Colombo M, Kobayashi M, Kumada H, Villanueva A, Llovet JM, Hoshida Y, and Friedman SL. A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection. Gut, 2015, in press. doi: 10.1136/gutjnl-2015-309655

 

Kocabayoglu K, Zhang DY, Kojima K, Hoshida Y, Friedman SL. Induction and contribution of b-PDGFR signaling by hepatic stellate cells to liver regeneration following partial hepatectomy in mice. Liver International, 2016, in press.

 

 

Review articles

 

Wallace MC, Hamesch K, Lunova, M, Kim Y, Weiskirchen R, Strnad P, Friedman SL. Standard operating procedures in experimental liver research: thioacetamide model in mice and rats. Laboratory Animals, 49 (1 suppl): 21-29, 2015.

 

Lee YM, Wallace MC, and Friedman SL.   Pathobiology of liver fibrosis, a translational success story. Gut, 64:830-841, 2015.

 

Friedman SL. Master’s Perspective; Principles on the Path to a Hepatologist’s Enlightenment. Hepatology, 62(1):8-12, 2015

 

Torok N, Dranoff JA, Schuppan D and Friedman SL. Strategies and endpoints of antifibrotic drug trials; summary and recommendations from the AASLD emerging trends conference. Hepatology, 62(2):627-34, 2015.

 

Wallace MC, Friedman SL, Mann DA. Emerging and disease-specific mechanisms of

hepatic stellate cell activation. Seminars in Liver Disease. 2015 May;35(2):107-18. doi:10.1055/s-0035-1550060. Epub 2015 May 14. PubMed PMID: 25974897

 

Friedman SL and Friedman YL. The future of hepatology: embrace change. Clinical Liver Disease, 5 (6):127–128, 2015.

 

Friedman SL. Clarity and challenges in tissue fibrosis.  Innovative Medicine, Nakao K. et al (eds.) Springer Plus, 978-4-431-55650-3, 323691_1_En, (16), in press, 2015.

 

Yoon YJ, Friedman SL, Lee YA. Antifibrotic Therapies: Where Are We Now? Seminars in Liver Disease. 2016 Feb;36(1):87-98. doi: 10.1055/s-0036-1571295. Epub 2016 Feb 12. PubMed PMID: 26870935.